Additional testing may be considered for people with a family history of premature heart disease, metabolic risk, abnormal cholesterol results, known cardiovascular disease, or uncertainty after standard testing: ApoB, Lp(a), and hs-CRP may help reveal particle burden, inherited risk, and inflammation that are not fully captured by LDL cholesterol alone
However, ganglionic blockers cannot be used chronically, given their unfavorable profile in terms of adverse effects
Experiencing these changes can be startling
PMOS (polyendocrime metabolic ovarian syndrome), previously known as PCOS, where excess weight is very common
Diarrhea was reported across all dose groups but was significantly more frequent and more severe at higher doses